Obsidian Therapeutics, Inc. Common Stock (OBX)

About Obsidian Therapeutics, Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Institutional ownership

In 13F filings for the quarter ended September 30, 2026, 11 institutions reported holding OBX, with 6.9 million shares worth $94.1 million in aggregate. The largest reported holder was Atlas Venture Life Science Advisors, with 4.5 million shares worth $61.8 million. Of the 5 largest holders listed below, all 5 opened new positions in OBX during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions